Cipla Ltd - CIPLA Share Price

Sector: Pharmaceuticals | ISIN: INE059A01026
₹ 1,354.85 (0.68%) icon22 Apr, 2024, 12:00:00 AM
Open
₹ 1,350.25
Prev. Close
₹ 1,345.75
Turnover(lac)
₹ 0.13
Day's High
₹ 1,361.95
Day's Low
₹ 1,348.00
52 Wk High
₹ 1,519.00
52 Wk Low
₹ 896.30
Book Value
₹ 342.79
Face Value
₹ 2.00
Mkt. Cap (Cr.)
₹ 109,389.91
P/E
33.25
EPS
40.73
Div. Yield
0.63

Cipla Ltd KEY RATIOS

sector: Pharmaceuticals

  • CMP

    as on 4/22/2024 12:00:00 AM

    ₹ 1354.85 9.10 0.68
  • Open
  • ₹ 1,350.25
  • Prev. Close
  • ₹ 1,345.75
  • Turnover(Lac.)
  • ₹ 0
  • Day's High
  • ₹ 1,361.95
  • Day's Low
  • ₹ 1,348
  • 52 Week's High
  • ₹ 1,519
  • 52 Week's Low
  • ₹ 896.3
  • Book Value
  • ₹ 342.79
  • Face Value
  • ₹ 2
  • Mkt Cap (₹ Cr.)
  • 109,389.91
  • P/E
  • 33.25
  • EPS
  • 40.73
  • Divi. Yield
  • 0.63

Cipla Ltd Corporate Actions

03 Jan , 2024

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

03 Jan , 2024

12:00 AM

06 Nov , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Oct , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

04 Oct , 2023

12:00 AM

11 Jul , 2023

12:00 AM

AGM

Announcement date: 11 Jul , 2023

View Details

04 Jul , 2023

12:00 AM

04 Jul , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

11 May , 2023

12:00 AM

Dividend

Dividend amount: 8.5
Announcement date: 11 May , 2023

View Details

12 Apr , 2023

12:00 AM

Board Meeting

Agenda: Audited Results

View Details

12 Apr , 2023

12:00 AM

No Record Found


Cipla Ltd News and Update

Image not found

Recommendation: Add; Target price: Rs 1345

Image not found

Cipla’s Samina Hamied quits as executive vice chairperson due to personal commitments

The corporation claimed "personal and family commitments" as the reason for her departure from her present post.

  • 29 Jan, 2024 |
  • 12:23 PM
Image not found

Cipla reports 32% y-o-y growth in net profit to Rs 1,056 crore; stock climbs to new 52-week

Its sales for the quarter increased 13.7% YoY to Rs 6,604 crore

  • 23 Jan, 2024 |
  • 10:11 AM
Image not found

Cipla-led arm recalls one lot of Vigabatrin owing to seal intergrity issue

An improper pouch seal may cause powder mix to leak outside the pouch

  • 11 Dec, 2023 |
  • 11:41 AM

Invest wise with Expert advice

mobile icon
  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required

Cipla Ltd SHAREHOLDING SNAPSHOT
23 April , 2024 | 12:39 AM

PROMOTER - TOTAL33.40%

Indian: 13.40%

Foreign: 19.9984%

NON-PROMOTER - TOTAL 66.39%

Institutions: 50.15%

Non-Institutions: 16.25%

CUSTODIES - 0.21%

Custodies: 0.21%

See More Details
ad IconAd Image

Cipla Ltd FINANCIALS

Cipla Ltd PEER COMPARISON

Figures of Market Capital(Mar Cap), Quaterly Net Profit(NP Qtr) and Quaterly Sales(Sales Qtr) are in ₹ Cr.View All Peer Comparison

MORE ABOUT Cipla Ltd

  • Y K Hamied
  • Chairman (Non-Executive)
  • M K Hamied
  • Vice Chairman
  • S Radhakrishnan
  • Non-Exec & Non-Independent Dir
  • Ashok Sinha
  • Non-Exec. & Independent Dir.
  • Peter Mugyenyi
  • Non-Exec. & Independent Dir.
  • Adil Zainulbhai
  • Non-Exec. & Independent Dir.
  • Punita Lal
  • Non-Exec. & Independent Dir.
  • Samina Hamied
  • Executive Vice Chairperson
  • Umang Vohra
  • Managing Director & Global CEO
  • Rajendra Chopra
  • Company Sec. & Compli. Officer
  • Robert A Stewart
  • Independent Director
  • P R Ramesh
  • Independent Director
  • Mandar Purushottam Vaidya
  • Independent Director

Summary

Cipla Ltd is one of the leading pharmaceutical companies in India. The Company is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). Ciplas product portfolio spans complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. With a rich portfolio, it is deepening presence in the home markets of India, as well as South Africa, North America, and other key regulated and emerging markets. Its 47 manufacturing sites around the world produce more than 50 dosage forms and over 1,500 products across wide range of therapeutic categories. Cipla Ltd was incorporated in the year 1935 with the name Chemical, Industrial & Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, the founder of Cipla gave the company all his patent and proprietary formulas for several drugs and medicines, without charging any royalty. On August 17, 1935, Cipla was registered as a public limited company with an authorized capital of Rs 6 lakh. From its first manufacturing unit at Bombay Central in 1936, Cipla now has over 40 state-of-the art manufacturing facilities across the globe including India, USA, China and South Africa.In the year 1941, as the Second World War cuts off drug supplies, the company starts producing fine chemicals, dedicating all its facilities for the war effort. In the year 1952, the company... Read More


Reports by Cipla Ltd


Reports by Cipla Ltd

Company FAQ

No Record Found